4//SEC Filing
Hanley Jr. Michael Conick 4
Accession 0001209191-22-047649
CIK 0001636282other
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 7:35 PM ET
Size
5.9 KB
Accession
0001209191-22-047649
Insider Transaction Report
Form 4
Hanley Jr. Michael Conick
Chief Commercial Officer
Transactions
- Award
Employee Stock Option (right to buy)
2022-08-23+130,000→ 130,000 totalExercise: $0.68Exp: 2032-08-22→ Common Stock (130,000 underlying)
Footnotes (1)
- [F1]The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.
Documents
Issuer
Aeglea BioTherapeutics, Inc.
CIK 0001636282
Entity typeother
Related Parties
1- filerCIK 0001791413
Filing Metadata
- Form type
- 4
- Filed
- Aug 24, 8:00 PM ET
- Accepted
- Aug 25, 7:35 PM ET
- Size
- 5.9 KB